Savara (NASDAQ:SVRA) Share Price Crosses Above Fifty Day Moving Average - Here's Why

Key Points

• Savara shares moved above their 50-day moving average, trading as high as $5.07 and last at $5.05, compared with a 50-day average of $4.98.
• Analyst sentiment is broadly positive: seven analysts rate SVRA a Buy and one a Sell, giving it a “Moderate Buy” consensus and an average price target of $10.25.
• Savara reported a quarterly loss of $0.16 per share, missing the consensus estimate of a $0.14 loss; institutional investors own about 87.9% of the stock.

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $4.98 and traded as high as $5.07. Savara shares last traded at $5.05, with a volume of 2,400,381 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SVRA shares. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a research report on Wednesday, October 7th. Citigroup reissued a "market outperform" rating on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a report on Wednesday, October 7th. They set an "overweight" rating and a $12.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Thursday, October 15th. Finally, Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research note on Sunday, October 4th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Savara currently has an average rating of "Moderate Buy" and an average target price of $10.25.

Savara Stock Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The firm has a market capitalization of $1.04 billion, a PE ratio of -8.71 and a beta of 0.32. The company's fifty day simple moving average is $4.98 and its 200 day simple moving average is $5.36.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, equities research analysts expect that Savara Inc. will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Nan Fung Trinity HK Ltd. grew its position in Savara by 1,088.3% during the third quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company's stock valued at $9,507,000 after acquiring an additional 1,687,310 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Savara in the 3rd quarter worth about $54,000. Profund Advisors LLC increased its position in shares of Savara by 7.3% during the third quarter. Profund Advisors LLC now owns 49,741 shares of the company's stock valued at $257,000 after acquiring an additional 3,370 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Savara by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company's stock worth $190,000 after purchasing an additional 4,874 shares in the last quarter. Finally, Moody Aldrich Partners LLC boosted its position in shares of Savara by 4.2% during the third quarter. Moody Aldrich Partners LLC now owns 502,932 shares of the company's stock valued at $2,595,000 after buying an additional 20,139 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara's lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.